Champions of Life Sciences Collaboration
Benchling came to Method as a promising startup developing a platform in the life sciences R&D cloud. They needed our help to raise their visibility and build their reputation as an essential asset to speed breakthroughs for life sciences organizations.

Capitalizing on Business Momentum
We capitalized on the moment of widespread innovation across the biotech sector to present Benchling as the key to manage complex biotech processes and accelerate collaboration for research teams working across COVID to CRISPR to climate change. Method hosted a media dinner that brought together eight top-tier reporters to meet Benchling’s executive team, investors and customers for an in-depth conversation to dig into Benchling’s platform and the market landscape. We developed a cadence of product announcements and business momentum stories that drove home how Benchling’s commitment to innovation was fueling growth.

Dominating Trade Presence
Amid the noisy news cycle of COVID-19, we helped Benchling punch through the noise with six stories in Forbes on the same day — including a feature and video associated with the “Next Billion-Dollar Startups” list. And Benchling has since been featured widely in core media such as Axios and Techcrunch, earned sustained visibility in life sciences publications and was named to the prestigious Cloud 100 list.


Today, the San Francisco-based company is one of 25 that made the cut for this year’s Forbes’ Next Billion-Dollar Startups list.
Financiers certainly see the benefit in Benchling’s technology — a new twist on what’s now a standard verticalized software as a service for a niche industry.
Groups can use tools such as the cloud-based software Benchling to plan and simulate Golden Gate and Gibson Assembly reactions.